CASTLE ROCK, Colo.,
Oct. 3, 2017 /PRNewswire/ -- Bioptix,
Inc (NASDAQ: BIOP) (the "Company"), announced today that its Board
of Directors has authorized a special dividend of approximately
$1.00 per common share (including
common share equivalents) in cash, payable on or about October 18, 2017 to shareholders of record as of
October 13, 2017.
Michael Beeghley, the Company's
Chairman and Chief Executive Officer, commented, "This special
dividend is a positive step to return value to all Bioptix
shareholders. We continue to explore options for delivering
additional value to shareholders with our streamlined overhead and
cash position."
The exact dividend total amount is subject to final calculation.
Shareholders do not need to take any action to receive the
dividend. Shares held in street name should receive the dividend by
credit to their brokerage accounts and shares held by shareholders
of record will receive a check. Equity Stock Transfer has been
appointed paying agent for administration of the dividend and any
questions should be directed to them at 212.575.5757 or
info@equitystock.com.
About Bioptix
The Company holds an exclusive
license from the University of
Washington in St. Louis
("UW") focusing on animal healthcare and owns important
intellectual property rights related to veterinary products and has
granted a license relating to single chain reproductive hormone
technology for use in non-human mammals which is under active
development by the licensee (bovine rFSH). The Company had
been involved in developing blood-based testing for diagnosis and
treatment of acute appendicitis until a negative response from the
FDA in 2015. The Company acquired BiOptix Diagnostics, Inc in
2016 and following a decision in 2017 to exit that business has
been reviewing possible strategic alternatives for that business,
including a possible sale. The Company has been reviewing
other strategic alternatives, including shifting its focus to new
technologies in unrelated markets.
Safe Harbor
The information provided in this press
release may include forward-looking statements relating to future
events or the future financial performance of the Company. Because
such statements are subject to risks and uncertainties, actual
results may differ materially from those expressed or implied by
such forward-looking statements. Words such as "anticipates,"
"plans," "expects," "intends," "will," "potential," "hope" and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based upon
current expectations of the Company and involve assumptions that
may never materialize or may prove to be incorrect. Actual results
and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of
various risks and uncertainties. Detailed information regarding
factors that may cause actual results to differ materially from the
results expressed or implied by statements in this press release
relating to the Company may be found in the Company's periodic
filings with the Securities and Exchange Commission, including the
factors described in the section entitled "Risk Factors" in its
annual report on Form 10-K for the fiscal year ended December 31, 2016, as amended and supplemented
from time to time and the Company's Quarter Reports on Form 10-Q
and other filings submitted by the Company to the SEC, copies of
which may be obtained from the SEC's website at www.sec.gov. The
parties do not undertake any obligation to update forward-looking
statements contained in this press release.
Media Contacts
Karen
Chase or Travis Kruse
Russo Partners, LLC
(646) 942-5627
(212) 845-4272
karen.chase@russopartnersllc.com
travis.kruse@russopartnersllc.com
View original
content:http://www.prnewswire.com/news-releases/bioptix-announces-special-cash-dividend-300529711.html
SOURCE Bioptix, Inc.